TPCS poised to triple
Shares Of Techprecision Are Poised To Triple
Dec. 22, 2013 8:56 PM ET | About: TPCS
Disclosure: I am long AAPL, OTCQB:TPCS. (More...)
(Editors' Note: This article covers a stock trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.)
During my time on Seeking Alpha, 10 of my 21 official picks to triple have doubled, tripled, or been acquired. Last week, Globalstar (OTCQB:GSAT) became #9. This week, Seagate (STX) became #10.
Based on significant breaking news, I believe Techprecision (OTCQB:TPCS) could soon become #11. I spoke with the company about the news on Friday afternoon. This article will discuss the news, its implications, and numerous other opportunities that should set the stage for shares of TPCS to triple in value.
On Thursday, privately-held Mevion reported on a major milestone in its quest to become the world's dominant supplier of proton-beam cancer therapy systems. Unbeknownst to most investors, this is big news for publicly-held Techprecision , which was awarded a 5 year, $115 million contract to be the exclusive manufacturer of Mevion's new S250 Proton Therapy System.
TechPrecision is a diversified manufacturer, specializing in the production of large components that require an abnormally high degree of precision. For the past several years, TPCS has been gearing up to ride the wave of several high-growth markets, including smart phones, Solar, Nuclear, Oil & Gas, and advanced cancer therapies.
After years of heavy lifting, the company finally appears well-positioned to reap the rewards.
Despite the company's many capabilities, its old management team seemed content to exist on a diet of one-off / custom projects with little or no lasting value. Turning that around required two things:
Market Data 
Markets 
AI
